

	Quarter ended 31-03-2017
	Rs. lacs
<b>I. Income</b>	
Revenue from operations (gross)	7,200.27
Less: Excise duty	195.92
<b>Revenue from operations (net)</b>	<b>7,004.35</b>
Other income	338.00
<b>Total revenue</b>	<b>7,342.35</b>
<b>II. Expenses</b>	
Cost of materials consumed	2,302.55
Purchase of stock in trade	1,337.72
Changes in inventories of finished goods and work-in-progress	155.55
Employee benefits expense	851.37
Finance costs	89.20
Depreciation and amortisation expense	224.11
Other expenses	1,465.09
<b>Total expenses</b>	<b>6,425.59</b>
<b>III. Profit / (loss) before tax</b>	<b>916.76</b>
<b>IV. Tax (expense)/Credit</b>	
Current Tax	(258.90)
Less: Minimum alternative tax credit entitlement	-
<b>Net Current Tax (Expense)/Credit</b>	<b>(258.90)</b>
Deferred Tax (Expense)/Income	485.47
<b>Total tax (expense)/Credit (net)</b>	<b>226.57</b>
<b>V. Net Profit/(Loss) for the period</b>	<b>1,143.33</b>
<b>VI. Paid-up equity share capital of Rs.10 each</b>	<b>802.91</b>
<b>VII. Earnings per share (nominal value of share Rs. 10) (not annualised)</b>	
Basic ( In Rs.)	14.24
Diluted ( In Rs.)	14.09

**NOTES :**

1. This result is prepared in connection with the direct listing of the Company to be filed with the BSE Limited (BSE) or may be shared with and relied on as necessary by the Merchant Bankers duly appointed in this regard or any other regulatory authority in connection with the direct listing.
2. The Company has received notice from BSE Limited (BSE) whereby the Company has been provided with an option to either complete the procedures for direct listing of its equity shares on nationwide stock exchange or provide exit to public shareholders by acquiring their equity shares at rates determined by independent valuer. Pursuant to receipt of such notice, the Company has initiated the procedures for direct listing of its equity shares on BSE.
3. **Basis of Accounting :-** For the purpose referred in note 1 above, the above financial results have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standards specified under Companies (Accounting Standard) Amendment Rules 2016, which is in line with the accounting policies adopted in preparation of financial statements at the year end. Further, the above financial results has been prepared with the purpose of summarizing performance of the Company for the three months period from 1 January 2017 to 31 March 2017. Accordingly, comparable figures for any of the previous periods have not been considered in above statement.
4. The above results were approved by the Board of Directors of the Company at their meeting held on 21.09.2017.
5. The operations of the Company represent a single primary business segment relating to pharmaceuticals.

For and on behalf of the board of directors of Zim Laboratories Limited

  
**Anwar S. Daud**  
Managing Director

  
**Zulfiqar M. Kamal**  
Director & CFO



Place: Nagpur  
Date: 21.09.2017